GlaxoSmithKline's Olympic Doping Facility to Research Personalised Medicines After Games

The anti-doping facility provided by GlaxoSmithKline (GSK) for the London 2012 Olympic and Paralympic Games will be turned into a research centre to develop personalised, targeted medicines after the sporting events finish. Funded and run by the UK’s Medical Research Council (MRC) and the Department of Health’s National Institute for Health Research (NIHR), the MRC-NIHR Phenome Centre will make use of GSK’s facilities in Harlow to analyse the metabolism of an individual or population set in an attempt to discover its link to how someone responds both to a disease and to treatment.

Back to news